AstraZeneca's Faslodex 500mg has received regulatory approval in Japan, for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer which has recurred or progressed following prior endocrine therapy, writes the company in a press statement.
In 2010 Faslodex 500 mg was approved in the US and Europe. The medication will be launched in Japan at the end of the year.
Tony Zook, Executive Vice President of AstraZeneca's Global Commercial Organisation said:
"We are very pleased to bring this important and well established medicine for the first time to doctors and their patients in Japan, our second largest market. The main goal of metastatic breast cancer treatment is to prevent disease progression while maintaining quality of life and Faslodex 500mg will give women the possibility of more control over their disease."
